Precision Medicine for Diffuse Large B-cell Lymphoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26988247.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0232.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study demonstrates the clinical utility of a targeted gene sequencing panel "the Lymphopanel," which enables the detection of actionable mutations and subtype-enriched gene alterations in diffuse large B-cell lymphoma that will pave the way to precision therapy era for patients with this form of aggressive lymphoma. Clin Cancer Res; 22(12); 2829-31. ©2016 AACRSee related article by Dubois et al., p. 2919.
Medical subject headings
- Lymphoma, Large B-Cell, Diffuse
- Molecular Targeted Therapy
- Precision Medicine